A5091727386- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Silicon Carbide Semiconductor Technologies
- Tumors and Oncological Cases
- Cancer Risks and Factors
- Neuroendocrine Tumor Research Advances
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Gastroesophageal reflux and treatments
- Peptidase Inhibition and Analysis
- Esophageal Cancer Research and Treatment
- Ovarian cancer diagnosis and treatment
- Esophageal and GI Pathology
- Cancer, Lipids, and Metabolism
- Cancer-related gene regulation
Hainan Medical University
2018-2025
Hainan Medical College Hospital
2021
Abstract Doxorubicin’s antitumor effectiveness may be constrained with ineffective tumor penetration, systemic adverse effects, as well drug resistance. The co-loading of immune checkpoint inhibitors and doxorubicin into liposomes can produce synergistic benefits address problems, including quick clearance, toxicity, low penetration efficiency. In our previous study, we modified a nanobody targeting CTLA-4 onto (LPS-Nb36) to an extremely potent signal blocker which improve the CD8 + T-cell...
Luteolin, a natural flavonoid compound, has demonstrated anti-inflammatory, antioxidant, and broad anti-tumor properties. Recent studies suggest that its effects are linked to enhanced CTL function-including proliferation, survival, cytotoxicity-via inhibition of the YAP/Wnt signaling pathway in tumor cells. Consequently, luteolin potential as an adjuvant combination therapies with adoptive immunotherapy. This study first assessed luteolin's tumor-inhibitory vitro vivo using cytotoxicity...
Despite the great success of CTLA-4 blocking in cancer treatment, use anti-CTLA-4 monoclonal antibodies still faces many limitations. Now, immune checkpoint coupled with adoptive cell therapy is gaining much attention. In this paper, we reported a strategy on basis nanobody (Nb)-modified liposomes to improve these obstacles. An Nb36/liposome complex was constructed and utilized as blocker CTLA-4/B7 signal pathway combination dendritic (DC)/tumor fusion vaccine enhance CD8+ T cytokine...
Cytokine-induced killer cells induced with tumor antigen-pulsed dendritic (DC-CIK) immunotherapy is a promising strategy for the treatment of malignant tumors. However, itsefficacy isrestricted by immunosuppression, which mediated cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) pathway. In order to overcome negative co-stimulation from these T cells,we screened nanobody targeted CTLA-4 (Nb36) and blocked signaling Nb36.Peripheral blood mononuclear (PBMCs) were collected healthy donors...
PurposCD105 has become a promising target of immunotherapy development for highly specific expression on the neovascular surface most types tumor cells. In previous studies, we constructed CAR T cell (CD105 cell) and observed significant antitumor activity. this study, optimized structure CD105 to increase PD-1 antibody secretion function × cells).Methodswe tested whether Increased with cells targeted could promote in vitro proliferation, proinflammatory cytokine production cytotoxicity,or...
Hereditary diffuse gastric cancer(HDGC) is a kind of malignant cancer that difficult to find in the early stage. However, this late onset and incomplete penetrance hereditary cancer, its prenatal diagnosis have rarely been reported previously.
CD105 has become a promising target of immunotherapy development for highly specific expression on the neovascular surface most types tumor cells. In previous studies, we constructed CAR T cell (CD105 cell) and observed significant antitumor activity. this study, optimized structure to increase PD-1 antibody secretion function × cells). Our data showed that secreted by cells could specifically bind receptor then blocked PD-1/PD-L-1 signaling pathway, thus enhancing activation proliferation...
Abstract Background: Cytokine-induced killer cells which were induced with tumor antigen-pulsed dendritic (DC-CIK) immunotherapy is a promising strategy for the treatment of malignant tumors. However, efficacy was restricted by immunosuppression microenvironment mediated cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) pathway. We, therefore, screened nanobody targeted CTLA-4 (Nb36), and blocked signaling Nb36 to overcome negative co-stimulation effector cells. Methods: Peripheral blood...